Results to your Biomarker
Matching services
Biomonitoring
In the field of human biomonitoring (HBM), we offer a comprehensive range of LC-MS and GC-MS-based methods tailored for the precise quantitative determination of environmental chemicals and their specific metabolites in various biological matrices, including urine, serum, plasma and saliva. Our commitment to accuracy and precision is what sets us apart. Our methods are routinely used in biomonitoring campaigns, allowing us to comprehensively assess both occupational and non-occupational exposures to environmental chemicals. At the heart of our services is a commitment to improving understanding of how these substances interact with the human body, ultimately promoting a healthier and more sustainable future.
Tobacco Harm Reduction
With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. Our methods are regularly applied in exposure and nicotine PK studies, supporting regulatory product submissions especially in the US under FDA CTP's PMTA and MRTPA. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.
Scientific Contribution
Assessing the exposure to ‘smoke’ from electronic cigarettes by biomarkers
CORESTA SSPT 2013, Seville, Spain
Biomarkers of Exposure Specific to E-vapor Products Based on Stable-Isotope Labeled Ingredients
Nicotine & Tobacco Research, Volume 21, doi: 10.1093/ntr/nty204
Biomarkers of exposure specific to e-vapor products based on stable-isotope labeled ingredients
SRNT 2018, Baltimore, USA
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients – methods
CORESTA SSPT 2017, Kitzbühel, Austria
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–results
CORESTA SSPT 2017, Kitzbühel, Austria
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–study design
CORESTA SSPT 2017, Kitzbühel, Austria
Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine
Cancer Epidemiology, Biomarkers & Prevention, Volume 27, doi: 10.1158/1055-9965
Saliva as a matrix for human biomonitoring in occupational and environmental medicine
International Archives of Occupational and Environmental Health, volume 88, doi: 10.1007/s00420-014-0938-5
Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites
Journal of Chromatography B, Volumes 951–952, doi: 10.1016/j.jchromb.2014.01.025
Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method
Journal of Proteome Research, Volume 13, doi: 10.1021/pr401099r
Assessment of nicotine delivery and uptake in users of various tobacco / nicotine products
Current Research in Toxicology, Volume 3, 100067